Is the British approach of prioritising first doses of Covid vaccines and not promising a second dose until 12 weeks later compromising our ability to fight the disease? It is not a moot point, with several EU figures asserting that it is a risky route to take.
As I wrote here a couple of weeks ago, as far as the AstraZeneca/Oxford vaccine is concerned, what evidence we have supports the practice of delaying a second dose until 12 weeks after the first one; the vaccine is more effective that way.
However, a question mark has continued to hang over the Pfizer/BioNTech vaccine. There is limited data on the most effective dosing regime in this case because the phase 3 trials did not experiment with delayed doses – everyone involved was given a second dose 21 days after the first.
An Israeli study
Get Britain's best politics newsletters
Register to get The Spectator's insight and opinion straight to your inbox. You can then read two free articles each week.
Already a subscriber? Log in
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in